anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Dadih contains BAL 108 CFU/ml which is probiotic. Consumption of functional bread and dadih's vla during pregnancy can improve the composition of the gut microbiota so that it can increase maternal weight and provide adequate nutrition during pregnancy. Good nutrient absorption can support good nutritional status and weight in babies who are born. This study aims to determine the effect of giving functional bread and dadih's vla on weight gain of pregnant women and birth weight of babies.

This study used a randomized controlled trial (RCT) design with a population of all pregnant women in the Kuranji, Nanggalo and Andalas Health Centers. The sample consisted of 88 people and was divided into two groups, namely the intervention group and the control group. Each amounted to 44 samples. The sample selection used the double-blind method and randomized controlled trial (RCT) research design. The intervention started at about 12-20 weeks of gestation and continued until just before the time of delivery. In the third trimester, subjects received healthy food, breastfeeding practices, and child development education to support mothers in maintaining their nutritional status, preparing exclusive breastfeeding, and optimizing child development.

Healthy babies born to mothers will be the focus of this study and followed up until the age of three months to assess their growth. The information includes the baby's health history after birth, anthropometric measurements, nutritional intake, and breastfeeding practices which are measured repeatedly in the first, second, and third months.

Data quality assurance is carried out through training starting from the period of data collection and supervision during and after data collection, including the data analysis process. This included training for enumerators, subjects and using a validated questionnaire for a group of subjects representing similar characteristics for this study. Data input and cleaning process will use excel and SPSS while for food intake data using NutriSurvey 2007. Data entry will be carried out by data collection officers after data collection. The data cleaning process includes removing outliers and regrouping multiple results that have similar meanings. The data will be interpreted as mean ± standard deviation if the data is normally distributed and the median (min-max) if the data is not normally distributed. Statistical analysis using SPSS 25 and data will be analyzed using univariate and bivariate analysis. Univariate analysis is used to describe characteristics and socio-demographics, medical history, pregnancy, and obstetric profiles of pregnant women. Numerical variables between groups will be analyzed using an Independent sample t-test if the data has normal distribution or the Mann Whitney test if the data distribution is not normal. Categorical variables between groups will be analyzed using Chi-square or Fisher test. Differences between birth and 3 months old follow up will be analyzed using independent t-tests if the data distribution has normal distribution or Mann Whitney test if the data distribution is not normal.
OBJECTIVE: To analyse the correlation between urinary albumin excretion rate (UAER) and estimated glomerular filtration rate (eGFR) and the risk factors for reducing eGFR in patients with type 2 diabetes mellitus (T2DM).
METHODS: A total of 431 T2DM patients admitted between January 2019 and March 2020 were selected and divided into two groups according to eGFR level. Comparing the differences between baseline data and clinical indicators, multivariate logistic regression was used to analyse the risk factors of eGFR reduction and to analyse the association between UAER and eGFR.
RESULTS: In total, 167 patients were included in the study group and 264 patients were included in the conventional group. The study group participants were older, had longer diabetes duration, and had higher fatty liver, peripheral vascular disease (PVD), hypertension prevalence, and mean body mass index (P < 0.05). The levels of various indicators were lower than those of the conventional group (P < 0. 05). Additionally, PVD, nocturnal systolic blood pressure, fatty liver, and beta-2-microglobulin (β 2-MG) were independent risk factors for eGFR decline, with high density lipoprotein (HDL) and fasting C-peptide (CP) as protective factors. There was no obvious correlation between UAER and eGFR.
CONCLUSION: Peripheral vascular disease, systolic blood pressure, fatty liver, and beta-2-microglobulin are risk factors for decreased eGFR levels in patients with T2DM, which should be applied for control DKD. HDL and fasting CP have important effects on maintaining eGFR, and blood pressure and fasting CP can be used as new targets for subsequent diabetic kidney disease treatment.
A method for identifying T cells having antigenic specificity for at least one neoantigen likely to be presented on the surface of a tumor cell in a subject. Obtaining a peptide sequence of a tumor neoantigen by sequencing tumor cells of the subject. Inputting the peptide sequence into a machine learning presentation model to generate presentation possibilities for the tumor neoantigen, each presentation possibility representing a likelihood that a neoantigen is presented by an MHC allele on the surface of a tumor cell of the subject. Selecting a subset of the neoantigens based on the presentation likelihood. Identifying T cells having antigenic specificity for at least one neoantigen in the subset. These T cells can be expanded for use in T cell therapy. The TCR of these identified T cells can also be sequenced and cloned into new T cells for use in T cell therapy.
FIELD: genetic engineering, virology, medicine. SUBSTANCE: invention relates to the improved retroviral vectors. Vectors are constructed on the basis of parent vectors MON and MIN based on MLV. Improved vectors are characterized by the presence of deletion in encoding regions MLV gag, pol and env that ensures to avoid the homologous recombination. Said vectors provide safety and effective expression of foreign genes. Vectors can be used in genetic therapy. EFFECT: improved and valuable properties of vectors. 13 cl, 13 dwg, 3 tbl, 3 ex
Chronic inflammation is a hallmark of cancer cachexia. Polyunsaturated fatty acids (ω-3 PUFAs): eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are known to contribute to the reduction of inflammation, preservation of lean body mass and total body weight, and reduction of cancer-related symptoms, such as anorexia or neuropathy. This systematic review aimed to assess whether the ratio of EPA to DHA used in supplementation in cancer patients matters in the context of the resolution of inflammation and reduction of the risk of cachexia. The analysis included 20 randomized clinical trials with acceptable quality identified from the Pubmed/MEDLINE database. The significant results concerning the resolution of inflammation or improvement in nutritional status were the highest in the case of a low EPA/DHA ratio, i.e., 67%, and decreased, reaching 50% and 36% for the moderate and high ratios, respectively. Most results concerning body weight from high and moderate EPA/DHA ratios showed no benefit or were insignificant. A significant benefit in reducing any reported inflammatory markers was seen in the low EPA/DHA ratio subgroup at 63%, in the moderate at 29%, and in the high ratio subgroup at 11%. The greatest benefit in CRP reduction was obtained by patients during chemotherapy. The review questions the anticachectic and anti-inflammatory effect of ω-3 PUFAs supplementation with doses of EPA higher than DHA. A population that particularly benefits from ω-3 PUFAs supplementation are patients undergoing chemotherapy for advanced cancer.
To address the need for scaffold-based oxygen concentration monitoring, a single-component, self-referenced oxygen sensor was made into nanofibers. Electrospinning process parameters were tuned to produce a biomaterial scaffold with specific morphological features. The ratio of an oxygen sensitive phosphorescence signal to an oxygen insensitive fluorescence signal was calculated at each image pixel to determine an oxygenation value. A single component boron dye-polymer conjugate was chosen for additional investigation due to improved resistance to degradation in aqueous media compared to a dye polymer blend. Standardization curves show that in fully supplemented media, the fibers are responsive to dissolved oxygen concentrations less than 15 parts per million. Spatial and temporal ratiometric gradients were observed in vitro radiating outward from the center of a dense adherent cell grouping. Sensor activation in ischemia and cell transplant models in vivo show oxygenation decreases on the scale of minutes.
PROBLEM TO BE SOLVED: To obtain an agent capable of specifically inhibiting cyclooxygenase-2 without inhibiting cyclooxygenase-1 activity. SOLUTION: This specific inhibitor of cyclooxygenase-2 contains 2-(2,6- dichloro-4-hydroxyanilino)phenylacetic acid expressed by the formula or its salt as an effective ingredient. As the compound of the formula does not inhibit cyclooxygenase-1 activity which synthesizes prostaglandin E2 produced in tunica mucosa ventriculi, etc., but specifically inhibits cyclooxygenase-2 which synthesizes prostaglandin E2 produced in an inflammatory region, the compound expresses excellent antiinflammatory effects without accompanied by adverse effects such as gastro-intestinal injuries. The compound is specifically effective for patients suffering from inflammations such as chronic articular rheumatism, etc. The dose is 20-200mg effective ingredient/day/adult and is preferably administered in once to several times a day. The compound can be administered per oral, per injection, per rectum, etc.
HYDANTOIN DERIVATIVES                           Abstract The 8-deutero, 8-tritio and 8-halo-substituted derivatives of d-6-fluoro-spiro-[chroman-4,4'-imidazolidine]          -2',5'-dione (sorbinil) have been prepared.  These compounds all have the 4S-configuration and are of value in the field of medicinal chemistry as aldose reductose inhibitors for the control of chronic diabetic complications.  More specifically, the novel compounds of this invention are selected from the group consisting of the 4S-isomers of asymmetric spiro-hydantoins of the formula:                                   (I) and the base salts thereof with pharmacologically acceptable cations, wherein X is deuterium, tritium of halogen (fluorine, chlorine, bromine or iodine).  The labeled 8-deutero and 8-tritio derivatives are useful in metabolism pharmacokinetic studies and in binding studies with the drug in animals and man.  The 8-halo derivatives are useful as intermediates for the labeled forms of the drug, in addition to being potent aldose reductose inhibitors per se.  Methods for the preparation of these compounds are pro-vided in some detail.
Developmental prosopagnosia (DP) is characterised by deficits in face identification. However, there is debate about whether these deficits are primarily perceptual, and whether they extend to other face processing tasks (e.g., identifying emotion, age, and gender; detecting faces in scenes). In this study, 30 participants with DP and 75 controls completed a battery of eight tasks assessing four domains of face perception (identity; emotion; age and gender; face detection). The DP group performed worse than the control group on both identity perception tasks, and one task from each other domain. Both identity perception tests uniquely predicted DP/control group membership, and performance on two measures of face memory. These findings suggest that deficits in DP may arise from issues with face perception. Some non-identity tasks also predicted DP/control group membership and face memory, even when face identity perception was accounted for. Gender perception and speed of face detection consistently predicted unique variance in group membership and face memory; several other tasks were only associated with some measures of face recognition ability. These findings indicate that face perception deficits in DP may extend beyond identity perception. However, the associations between tasks may also reflect subtle aspects of task demands or stimuli.
SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
A major factor in the pathogenesis of asthma is the development of an allergic inflammatory response to inhaled antigens. Interleukin-4 (IL-4) plays a key role in this response. Binding and inactivating the IL-4 molecule with IL-4R may diminish the allergic asthmatic response by inhibiting activities of IL-4.

Patients are randomized to 1 of 3 treatment groups and, within each group, are stratified by baseline FEV1 cohort. Patients receive either dose level 1 of IL-4R, dose level 2 of IL-4R, or placebo, by aerosol drug delivery device, once a week for 12 weeks. There are frequent clinic visits and several follow-up visits. Physical exams and spirometry are done regularly; immunizations are administered on Day 28; and a skin tests panel is given on Day 84. Blood samples are collected at study visits during treatment and follow-up to test for immunology/serology parameters, chemistry profiles, and asthma-related DNA polymorphisms. Patients are provided with peak flow meters and must demonstrate their proper use so that a peak expiratory flow (PEF) diary and a symptoms diary can be maintained. Selected sites measure exhaled nitric oxide and collect induced sputum samples. Assessments for adverse events are conducted at 16 and 40 weeks following the first study drug treatment.
PURPOSE: The aim of the current scoping review is to identify the studies reporting ototoxicity monitoring in individuals with head and neck cancer (HNC) undergoing radiation therapy and/or chemoradiation therapy across the world. The specific objectives were to identify and report the test protocol used, identify the most common timeline of follow-up, and identify barriers and facilitators influencing the implementation of the monitoring program.
METHOD: A comprehensive search was conducted across six electronic databases, including PubMed, Embase, Web of Science, Scopus, Google Scholar, and ProQuest. The scoping review method adhered to relevant guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) and frameworks. The database search was carried out by two independent researchers, and studies were selected based on specific inclusion and exclusion criteria.
RESULTS: This scoping review identified 13 studies that fulfilled the inclusion criteria of this study. Only one study reported findings from the perspective of ototoxicity monitoring. Another study explicitly mentioned that ototoxicity monitoring was a standard of care in their hospital. Only one study reported using the relevant guidelines for monitoring ototoxicity. Specialized tests such as high-frequency audiometry, distortion product otoacoustic emissions, and vestibular tests were rarely used. Ototoxicity monitoring was influenced by awareness-related factors, technical factors, treatment-related factors, and organizational factors.
CONCLUSIONS: Research on ototoxicity monitoring programs is in its early stages, highlighting the need for standardized practices and multidisciplinary collaboration to enhance health care services for HNC patients. A standardized approach, improved awareness, and the incorporation of patient perspectives are crucial to enhancing ototoxicity monitoring in HNC patients.
Ninety patients scheduled to undergo moderately painful surgery were included in one of three groups. Determination of median effective (ED50) doses was performed by the Dixon and Mood up-and-down method. Initial doses were 1.5g and 5mg, with dose adjustment intervals of 0.5g and 1 mg, in the paracetamol and morphine groups, respectively. The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine. Analgesic efficacy was defined as a decrease to less than 3 on a 0-10 numeric pain scale, 45 min after the beginning of drug administration. Isobolographic analysis was used to define the nature of their interaction.
1411421 Urokinase-heparin complex CHOAY SA 22 Sept 1972 [24 Sept 1971 30 June 1972 (2)] 44003/72 Heading C3H [Also in Division A5] A complex of urokinase and heparin is prepared by admixing a solution of urokinase and a solution of heparin, adjusting the pH of the mixed solutions, e.g. with phosphoric acid, to from 1 to 5, preferably about 4.2, for formation and precipitation of the complex and, if desired, freeze-drying the complex. The complex may have typical relative activities of 30,000-100,000 CTA units of -urokinase per 100 IU of heparin. A solution for perfusion comprises the complex dissolved in a pharmaceutically acceptable, isotonic solution, e.g. 5% glucose serum, which is compatible with urokinase, does not form a precipitate with heparin and is free of mineral salts. The solutions may have urokinase concentrations of the order 300,000-900,000 CTA units/250 ml. Methods for obtaining a pyrogenic urokinase as starting material for the complex formation are described in detail. They may involve extracting crude urokinase from human urine by absorption on diatomaceous earth and elution of urokinase therefrom, elimination of viral contamination as by heating to 60C. under slightly acid conditions and cooling and separating off the solid residue, and two steps of fractionation using diethylaminoethyl cellulose employing in the first step suspensions of pH 4-6 and conductivity 15,000-25,000 micromhos/cm. with 15-40 g. of resin per 14 million CTA units of urokinase, and in the second step suspensions of pH 6-7 and conductivity 15,000-18,000 micromhos/cm. with 30-60 g. of resin per 10 million CTA units of the enzyme. The resulting urokinase-containing medium is diluted with quantities of water sufficient to lower the conductivity by about 1000 microinhos/cm. at each successive dilution until a suspension having a conductivity of about 9,000 micromhos/cm. is obtained.
The present invention relates to a natural eyebrow tattooing method and natural color eyebrow tattooing liquid used in the method. The natural eyebrow tattooing method uses an oblique S-shaped double-tattooing method for an eyebrow head, a crossed upward inclined tattooing method for the middle part of an eyebrow and a leaf or stem grain tattooing method for an eyebrow end to tattoo the eyebrow according to the natural growth rhythm of the eyebrow. The natural color eyebrow tattooing liquid is used in the eyebrow tattooing method and contains chloramphenicol, orthoboric acid, sodium tetraborate decahydrate, thiomersal, sterile purified water, etc. The eyebrow tattooed by the present invention has soft and natural color and clear and smooth line and has vivid effects. In addition, anesthetic is not required during eyebrow tattooing and tattooing time is short. After finished, a tattoo can be cleaned by water immediately. No redness, swelling, pain or scars exist.
Loss of proteostasis and dysregulated mitochondrial function are part of the traditional hallmarks of aging, and in their last revision impaired macroautophagy and chronic inflammation are also included. Mitophagy is at the intersection of all these processes but whether it undergoes age-associated perturbations was not known. In our recent work, we performed a systematic and systemic analysis of mitolysosome levels in mice and found that, despite the already-known decrease in nonselective macroautophagy, mitophagy remains stable or increases upon aging in all tissues analyzed and is mediated by the PINK1-PRKN-dependent pathway. Further analyses revealed a concomitant increase in mtDNA leakage into the cytosol and activation of the CGAS-STING1 inflammation axis. Notably, both phenomena are also observed in primary fibroblasts from aged human donors. We hypothesized that mitophagy might be selectively upregulated during aging to improve mitochondrial fitness and reduce mtDNA-induced inflammation. Treatment with the mitophagy inducer urolithin A alleviates age-associated neurological decline, including improved synaptic connectivity, cognitive memory and visual function. Supporting our initial hypothesis, urolithin A reduces the levels of cytosolic mtDNA, CGAS-STING1 activation and neuroinflammation. Finally, using an in vitro model of mitochondrial membrane permeabilization we validated that PINK1-PRKN-mediated mitophagy is essential to resolve cytosolic mtDNA-triggered inflammation. These findings open up an integrative approach to tackle aging and increase healthspan via mitophagy induction.
This is a single-center, open-label, randomized, parallel-group, active-control, phase 1 study consisting of 10-day treatment period using TBPM-PI-HBr (600mg) (2× 300mg film coated tablets) or amoxicillin-clavulanate (500mg/125mg) orally every 8 hours (PO q8h \[±1 hour\]) in healthy volunteers. Participants will be randomized by gender to 1:1 ratio on Day 1. A maximum of 30 participants will be randomly assigned to the study treatment groups (15 in each arm) such that approximately 24 evaluable participants complete the study. Due to the multidimensional nature of data of the study, a power statement on a single endpoint is not appropriate. The main aim of the study is to estimate the effects of treatment on the intestinal microbiota, and to assess the pattern of susceptibility to specific pathogens. Based upon previous studies, a sample size of 12 participants in each group is considered sufficient to demonstrate a clinically significant impact of antibiotics on the microbiota. Total duration of study participation for each participant will be approximately 7 months.Screening visit will be performed between Day -28 to Day -1. Randomization will be performed on Day 1 and with treatment being administered from Day 1 to Day 10. Follow-up of participants will occur on Day 14, 21, 90 and 180 with appropriate visit windows. Adverse events and concomitant medications will be recorded until the end of the study (Day 180).